[ACCESSWIRE]
CORAL GABLES, FL / ACCESSWIRE / February 4, 2015 / Weed is now legal by popular vote in Washington, Colorado, Oregon, and Alaska's anticipated market is slated for full implementation in the near future. It's no surprise that people want to get in on the "ground floor" of the industry and though not everyone has the locale to open up their own storefront, the public markets have offered opportunity for investment into companies that do. Over recent weeks, may of these stocks have begun to rally and are piquing the interests of new and old pot traders market wide.
CannaGrow Holdings (OTCPINK:CGRW) announced that the company and NuGro Industries have entered into an agreement to purchase the first of two 3,300 sq. ft. greenhouses manufactured by Nexus Greenhouse Systems. According to the company, CannaGrow would be provided with a basis to begin generating revenues from licensed growers sub-leasing these "turnkey" grow facilities. Bear in mind that this has been a process that the company has been progressing with since November of last year and since this period, the share price has risen more than 10-fold. In fact, since November 3, CannaGrow shares have moved up by as much as 1,050%.
Inergetics, Inc. (OTCBB: NRTI) announced Tuesday morning that it is completing the final development phase for its new Cannabidiol-based pain relief product. According to the release, the company has marked "significant progress in readying its first natural CBD-based nutraceutical supplement for introduction to the marketplace."
This announcement has sparked "significant progress" in the market as well. Since the beginning of the week, shares of Inergetics have taken off. From Monday's open to highs on Tuesday, NRTI has seen an increase in price by as much as 100%.
In line with Inergetics, PharmaCyte Biotech, Inc. (OTCQB:PMCB) has also reported progress for its own novel drug treatment. The company is focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box(R) . Monday morning PharmaCyte reported that the first preclinical evaluation of its proprietary Melligen cell line for the treatment of diabetes has commenced. It will be held in the Institute of Virology, Department of Pathobiology, at the University of Veterinary Medicine in Vienna, Austria. Since making this announcement, shares have jumped by as much as 14% and on above average volume for the stock's trailing 3-month volume.
About marijuanastocks.com
MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. DAMJ VENTURES LLC which owns www.MarijuanaStocks.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.
DAMJ VENTURES LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. DAMJ VENTURES LLC which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Contact Information:
marijuanastocks.com
800-539-4313
[email protected]
SOURCE: MarijuanaStocks.com
